OA12.05 Improved in vitro expression and in vivo immunogenicity of a candidate MVA-vectored HIV-1 vaccine compared to SAAVI MVA-COral Abstract SessionNovel vaccine and other prevention approaches
OA13.01 Implementing a rapid response to the COVID-19 global pandemic in MTN-034/REACH: an HIV prevention trial among adolescent girls and young women in AfricaOral Abstract SessionEthics in HIV prevention research
OA13.02 Social, economic, mental health and medical care impacts of COVID-19 in a US cohort of sex and gender diverse adolescents and young adults at-risk for HIVOral Abstract SessionBehavioural and social science research
OA13.03 Acceptability of telemedicine and HIV self-test among PrEP users during the COVID-19 pandemic in BrazilOral Abstract SessionImplementation science, including structural interventions, PrEP & VMMC
OA13.04 The COVID-19 pandemic and transition to telehealth: appointment attendance and patient perspectives at an adult HIV clinicOral Abstract SessionBehavioural and social science research
OA13.05LB Utilizing a robust HIV prevention community engagement framework to engage communities in COVID-19 prevention effortsOral Abstract SessionCommunity engagement in prevention research
OA14.01 Improved killing of HIV-infected cells by a combination of three neutralizing and non-neutralizing antibodiesOral Abstract SessionTherapeutic vaccines, viral reservoirs and eradication/remission
OA14.02 Unprimed CD8+ lymphocytes promote the maintenance of HIV latency in CD4+ T cellsOral Abstract SessionTherapeutic vaccines, viral reservoirs and eradication/remission
OA14.03 Analysis of the early responses to HIV-1 in matched treatment naïve individuals reveals early soluble proteins that are associated with in vivo virus controlOral Abstract SessionInnate and trained immunity
OA14.04 Targeting Sphingosine-1-phosphate signaling prevents cell-to-cell transmission of HIV-1Oral Abstract SessionTherapeutic vaccines, viral reservoirs and eradication/remission
seek-warrow-warrow-eseek-e61 - 70 of 444 items